Table 2.
Age-adjusted prevalence of demographic, lifestyle, and clinical characteristics of breast cancer patients by presence of any menopausal symptom (MPSa) at 6 and 36 months postdiagnosis, the SBCSS
| Characteristics | Any MPS at 6 months n = 4,842 |
Any MPS at 36 months n = 3,472 |
||||
|---|---|---|---|---|---|---|
| Yes (n = 2,710) | No (n = 2,132) | P* | Yes (n = 2,187) | No (n = 1,285) | P* | |
| 56.0% | 44.0% | 63.0% | 37.0% | |||
| Age at cancer diagnosis (mean ± SD) | 51.4±8.2 | 55.6±10.4 | < 0.01 | 51.7±8.5 | 56.4±11.8 | < 0.01 |
| Education | ||||||
| ≤Primary | 3.9 | 3.8 | 3.5 | 3.9 | ||
| Middle school | 7.8 | 8.4 | 8.5 | 9.4 | ||
| High school or technical training | 73.2 | 71.7 | 73.6 | 71.6 | ||
| ≥College | 15.1 | 16.0 | 0.62 | 14.4 | 15.1 | 0.66 |
| Education | ||||||
| ≤Primary | 27.7 | 29.1 | 30.1 | 29.4 | ||
| Middle school | 30.9 | 28.9 | 31.2 | 29.8 | ||
| High school or technical training | 29.8 | 30.6 | 28.8 | 28.6 | ||
| ≥College | 11.6 | 11.4 | 0.48 | 9.9 | 12.2 | 0.21 |
| Parity (%) | ||||||
| Nulliparous | 0.9 | 0.8 | 5.2 | 3.8 | ||
| 1 | 72.7 | 67.8 | 67.9 | 64.8 | ||
| 2 | 15.3 | 19.2 | 15.3 | 18.5 | ||
| ≥3 | 11.1 | 12.2 | < 0.01 | 11.6 | 12.9 | < 0.01 |
| Menopausal status | ||||||
| Premenopausal | 52.9 | 46.9 | 18.8 | 28.5 | ||
| Postmenopausal | 47.1 | 53.1 | < 0.01 | 81.2 | 71.5 | < 0.01 |
| BMI, kg/m2 (mean) | 23.8 | 23.9 | 0.35 | 24.5 | 24.0 | 0.34 |
| Regular physical activity | 64.0 | 64.6 | 0.76 | 66.6 | 67.8 | 0.47 |
| Regular smoker | 2.7 | 2.3 | 0.45 | 2.2 | 2.4 | 0.60 |
| Regular alcohol drinker | 3.3 | 1.6 | 0.12 | 2.7 | 2.6 | 0.94 |
| Charlson co-morbidity index ≥1 | 21.0 | 18.8 | 0.05 | 21.5 | 18.8 | 0.04 |
| Total meat intake, g/day (mean) | 366.1 | 349.4 | 0.02 | 219.6 | 213.8 | 0.29 |
| Soy isoflavone intake, mg/day (mean) | 47.1 | 45.7 | 0.39 | 47.6 | 46.6 | 0.46 |
| Self-reported quality of life | ||||||
| Poor | 9.3 | 7.2 | 8.6 | 6.5 | ||
| Average | 73.7 | 72.5 | 75.1 | 71.9 | ||
| Good | 17.0 | 20.3 | < 0.01 | 16.3 | 21.6 | 0.002 |
| Vitamin supplement user | 29.9 | 27.7 | 0.19 | 31.8 | 28.6 | 0.05 |
| Received chemotherapy | 91.6 | 90.5 | 0.19 | 91.2 | 90.8 | 0.75 |
| Received immunotherapy | 16.2 | 12.6 | < 0.01 | 15.2 | 13.4 | 0.21 |
| Tamoxifen user | 56.9 | 45.1 | < 0.01 | 77.2 | 72.5 | 0.03 |
| Stage, TNM | ||||||
| 0–I | 37.7 | 35.5 | 37.5 | 37.5 | ||
| II | 48.7 | 50.1 | 50.5 | 49.9 | ||
| III | 8.8 | 9.7 | 7.5 | 8.3 | ||
| Missing | 4.8 | 4.7 | 0.41 | 4.5 | 4.3 | 0.88 |
| Hormone receptor status | ||||||
| ER−/PR− | 25.9 | 30.5 | 24.6 | 29.6 | ||
| ER+/PR+ | 52.3 | 46.6 | 53.2 | 48.7 | ||
| ER±/PR± mixed | 20.3 | 20.4 | 20.7 | 19.9 | ||
| Missing | 1.5 | 2.5 | < 0.01 | 1.5 | 1.8 | 0.03 |
*
P values were derived from the ANOVA procedure for continuous variables and the CMH test for categorical variables, except for age
a
Any menopausal symptom (MPS) included 1 or ≥2 vasomotor symptoms, including hot flashes, night sweats, and vaginal dryness
Note: Menopausal status, BMI, tamoxifen use (cumulative), and isoflavone intake (weighted average) were calculated at both 6 and 36 months postdiagnosis